MCID: PSY004
MIFTS: 74

Psychotic Disorder

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Psychotic Disorder

MalaCards integrated aliases for Psychotic Disorder:

Name: Psychotic Disorder 12 15
Mental or Behavioural Disorder 12 17
Psychotic Disorders 44 74
Mental Disorders 74
Psychotic 56

Classifications:

ICD10: 34


Summaries for Psychotic Disorder

MedlinePlus : 44 Psychotic disorders are severe mental disorders that cause abnormal thinking and perceptions. People with psychoses lose touch with reality. Two of the main symptoms are delusions and hallucinations. Delusions are false beliefs, such as thinking that someone is plotting against you or that the TV is sending you secret messages. Hallucinations are false perceptions, such as hearing, seeing, or feeling something that is not there. Schizophrenia is one type of psychotic disorder. People with bipolar disorder may also have psychotic symptoms. Other problems that can cause psychosis include alcohol and some drugs, brain tumors, brain infections, and stroke. Treatment depends on the cause of the psychosis. It might involve drugs to control symptoms and talk therapy. Hospitalization is an option for serious cases where a person might be dangerous to himself or others.

MalaCards based summary : Psychotic Disorder, also known as mental or behavioural disorder, is related to schizophreniform disorder and delusional disorder, and has symptoms including photophobia, agitation and lethargy. An important gene associated with Psychotic Disorder is COMT (Catechol-O-Methyltransferase), and among its related pathways/superpathways are Circadian entrainment and Beta-Adrenergic Signaling. The drugs Prednisolone and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are no effect and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 A cognitive disorder that involves abnormal thinking and perceptions resulting in a disconnection with reality.

Wikipedia : 77 Psychosis is an abnormal condition of the mind that results in difficulties determining what is real and... more...

Related Diseases for Psychotic Disorder

Diseases related to Psychotic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 322)
# Related Disease Score Top Affiliating Genes
1 schizophreniform disorder 33.4 COMT DRD2 NRG1 PRL
2 delusional disorder 32.4 DRD2 DRD3 DRD4
3 schizophrenia 2 31.9 DISC1 DRD3
4 schizoaffective disorder 31.4 BDNF COMT DAOA DISC1 DRD2 DRD3
5 anxiety 30.9 BDNF COMT HTR2A SLC6A4
6 traumatic brain injury 30.8 BDNF COMT DRD2
7 depression 30.8 BDNF HTR2A SLC6A4
8 brain injury 30.8 BDNF COMT DRD2
9 tardive dyskinesia 30.6 COMT DRD2 DRD3 HTR2A
10 schizophrenia 30.5 BDNF COMT DAO DAOA DISC1 DRD1
11 postpartum depression 30.4 BDNF COMT PRL SLC6A4
12 substance abuse 30.3 BDNF COMT DRD2 DRD3 DRD4 PRL
13 borderline personality disorder 30.3 BDNF COMT HTR2A SLC6A4
14 mental depression 30.3 BDNF COMT HTR2A SLC6A4
15 anorexia nervosa 30.2 BDNF COMT HTR2A PRL SLC6A4
16 alexithymia 30.2 COMT DRD2 SLC6A4
17 autism 30.2 BDNF HTR2A NRXN1 SLC6A4 SYN2
18 galactorrhea 30.1 DRD2 PRL
19 autism spectrum disorder 30.1 BDNF HTR2A NRXN1 SLC6A4
20 cocaine dependence 30.1 DRD2 DRD3 SLC6A4
21 personality disorder 30.1 BDNF COMT DRD2 DRD4 HTR2A PRL
22 post-traumatic stress disorder 30.1 BDNF COMT DRD2 HTR2A MAOB SLC6A4
23 tic disorder 30.1 DRD2 DRD4 HTR2A
24 paranoid schizophrenia 30.1 BDNF COMT HTR2A SLC6A4
25 endogenous depression 30.0 BDNF HTR2A SLC6A4
26 substance-induced psychosis 30.0 DRD2 HTR2A
27 substance dependence 29.9 BDNF DRD2 DRD3 DRD4 SLC6A4
28 mood disorder 29.9 BDNF COMT DAOA DISC1 DRD2 DRD3
29 drug dependence 29.9 BDNF DRD2 DRD3 SLC6A4
30 eating disorder 29.9 BDNF COMT DRD2 SLC6A4
31 early-onset schizophrenia 29.9 BDNF DRD1 DRD2 HTR2A
32 serotonin syndrome 29.9 HTR2A MAOB SLC6A4
33 pervasive developmental disorder 29.9 BDNF NRXN1 SLC6A4
34 chronic fatigue syndrome 29.9 COMT HTR2A SLC6A4
35 heroin dependence 29.8 BDNF DRD2 DRD4
36 conduct disorder 29.8 COMT DRD2 DRD4 SLC6A4
37 tobacco addiction 29.7 COMT DRD2 HTR2A NRXN1 SLC6A4
38 parkinson disease, late-onset 29.7 BDNF COMT DRD1 DRD2 DRD3 HTR2A
39 generalized anxiety disorder 29.7 BDNF COMT DRD2 HTR2A SLC6A4
40 bipolar disorder 29.7 BDNF COMT DAO DAOA DISC1 DRD2
41 major depressive disorder 29.6 BDNF COMT DISC1 DRD2 DRD3 DRD4
42 disease of mental health 29.6 BDNF COMT DISC1 DRD2 DRD3 DRD4
43 obsessive-compulsive disorder 29.5 BDNF COMT DRD1 DRD2 DRD3 DRD4
44 alcohol dependence 29.4 BDNF COMT DRD1 DRD2 DRD3 DRD4
45 bipolar i disorder 29.3 BDNF COMT DAO DRD1 DTNBP1 HTR2A
46 alcohol abuse 29.3 BDNF DRD1 DRD2 DRD3 DRD4 HTR2A
47 attention deficit-hyperactivity disorder 29.2 BDNF COMT DRD1 DRD2 DRD3 DRD4
48 phenylketonuria 11.3
49 norrie disease 11.2
50 drug psychosis 11.2

Graphical network of the top 20 diseases related to Psychotic Disorder:



Diseases related to Psychotic Disorder

Symptoms & Phenotypes for Psychotic Disorder

UMLS symptoms related to Psychotic Disorder:


photophobia, agitation, lethargy, restlessness, personality changes, pseudobulbar behavioral symptoms, sleep disturbances, mental and behavioral signs and symptoms, forgetful, decrease in appetite, nervousness, feeling jittery, symptoms, alexithymia, increased libido, numbness, psychiatric symptom, hallucinations, auditory, hallucinations, visual, numbness localized, feeling detached, feeling strange, feeling weightless, floating feeling, dejection emotional, depressed reaction, hallucinations, sensory, restless sleep, difficulty sleeping, excitability, depression aggravated, agitation mental, numb mouth, opiate withdrawal symptoms, clouded consciousness, trembling inside, sluggishness, catatonic reaction

GenomeRNAi Phenotypes related to Psychotic Disorder according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 BDNF COMT DAO DAOA DISC1 DRD1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 9.7 PRODH
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.7 PRODH
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.7 PRODH
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 9.7 PRODH
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.7 DRD3 PRODH
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-58 9.7 DRD3 DRD4 PRODH
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-66 9.7 PRODH
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-86 9.7 PRODH

MGI Mouse Phenotypes related to Psychotic Disorder:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.28 BDNF COMT DAO DISC1 DRD1 DRD2
2 homeostasis/metabolism MP:0005376 10.16 BDNF COMT DAO DISC1 DRD1 DRD2
3 nervous system MP:0003631 9.89 BDNF COMT DAO DISC1 DRD1 DRD2
4 integument MP:0010771 9.76 BDNF DRD1 DRD2 DTNBP1 PRL PRODH
5 renal/urinary system MP:0005367 9.17 COMT DRD2 DRD3 DTNBP1 MAOB RGS4

Drugs & Therapeutics for Psychotic Disorder

Drugs for Psychotic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1085)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisolone Approved, Vet_approved Phase 4,Phase 1,Phase 2 50-24-8 5755
2
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 1,Phase 2 302-25-0
3
Methylprednisolone Approved, Vet_approved Phase 4,Phase 1,Phase 2 83-43-2 6741
4
Methylprednisolone hemisuccinate Approved Phase 4,Phase 1,Phase 2 2921-57-5
5
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129722-12-9 60795
6
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
7
Asenapine Approved Phase 4,Phase 3,Phase 2,Phase 1 65576-45-6, 85650-56-2 3001386
8
Ziprasidone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 146939-27-7 60854
9
Linagliptin Approved Phase 4,Phase 1 668270-12-0 10096344
10
Amisulpride Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 71675-85-9, 53583-79-2 2159
11
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61869-08-7 43815
12
Sertraline Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 79617-96-2 68617
13
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 54910-89-3 3386
14
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59729-33-8 2771
15
Fluvoxamine Approved, Investigational Phase 4,Phase 2,Not Applicable 54739-18-3 3404 5324346
16
Haloperidol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-86-8 3559
17
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 132539-06-1 4585
18
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99-66-1 3121
19
Lithium carbonate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 554-13-2
20
Oxcarbazepine Approved Phase 4,Phase 2,Phase 3 28721-07-5 34312
21
Coal tar Approved Phase 4,Phase 2,Not Applicable 8007-45-2
22
Zolpidem Approved Phase 4,Phase 3,Phase 2,Not Applicable 82626-48-0 5732
23
Diphenhydramine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147-24-0, 58-73-1 3100
24
Risperidone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 106266-06-2 5073
25
Promethazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 60-87-7 4927
26
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 113-45-1 4158
27
Chlorpromazine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-53-3 2726
28
Modafinil Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 68693-11-8 4236
29
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1 120014-06-4 3152
30
Guanfacine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 29110-47-2 3519
31
Etomidate Approved Phase 4,Not Applicable 33125-97-2 36339 667484
32
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2078-54-8 4943
33
Clozapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 5786-21-0 2818
34
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
35
Reboxetine Approved, Experimental Phase 4,Phase 2,Phase 1,Not Applicable 98769-81-4, 71620-89-8 65856 123628
36
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 10118-90-8 5281021
37
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-41-2 439260
38
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-18-4 6010
39
Testosterone Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-22-0, 481-30-1 6013 10204
40
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 315-37-7 9416
41
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 5949-44-0
42
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 148553-50-8 5486971
43
Trazodone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 19794-93-5 5533
44
Ketamine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 6740-88-1 3821
45
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-66-6 32051
46
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
47
Oxytocin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-56-6 439302 53477758
48
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1401-55-4
49
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 94-09-7, 1994-09-7 2337
50
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68-04-2

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry Unknown status NCT00986167 Phase 4 Quetiapine XR
2 Prednisolone Addition for Patients With Recent-onset Psychotic Disorder Unknown status NCT02949232 Phase 4 Prednisolone;Placebo Oral Tablet
3 Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis Unknown status NCT01119014 Phase 4 Aripiprazole;Quetiapine
4 Investigator Initiated Study - Asenapine Early Psychosis Unknown status NCT01968161 Phase 4 Asenapine
5 The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation Unknown status NCT02935998 Phase 4 Ziprasidone
6 Omega-3 Fatty Acids Efficacy in First-episode of Schizophrenia Unknown status NCT02210962 Phase 4
7 A Pharmacokinetic Study of Paliperidone ER Unknown status NCT02433717 Phase 4 Paliperidone ER
8 Linagliptin and Mesenchymal Stem Cells: A Pilot Study Unknown status NCT02442817 Phase 4 Linagliptin
9 Association of Amisulpride Response in Schizophrenia With Brain Image Unknown status NCT02095938 Phase 4 amisulpride
10 Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients Unknown status NCT02022709 Phase 4 Fluoxetine;Sertraline;Paroxetine;Citalopram;Fluvoxamine
11 Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS) Unknown status NCT01250847 Phase 4 Quetiapine(Seroquel-XR) 50~800mg a day
12 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder Unknown status NCT00437099 Phase 4 Omacor®;Placebo
13 The Effect of a Community-based LAI-treated Management Model on the Violence Risk of Patients With Schizophrenia Unknown status NCT03080194 Phase 4 paliperidone palmitate;control group
14 Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia Unknown status NCT00838032 Phase 4 Quetiapine fumarate;Haloperidol
15 Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
16 Tolerability And Efficacy Of High Dose Escitalopram In The Treatment Of Patients Suffering From Schizophrenia And Obsessive-Compulsive Disorder (OCD) - An Open Label Study Unknown status NCT00708396 Phase 4 Escitalopram
17 Risperidone and Zotepine in the Treatment of Delirium Unknown status NCT00622011 Phase 4 Risperidone and Zolpidem for delirium
18 Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4 Methylphenidate;Risperidone
19 A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
20 Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm Unknown status NCT01016145 Phase 4 Antipsychotics;Antipsychotics
21 High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone Unknown status NCT00539071 Phase 4 long-acting injectable risperidone;long acting injectable risperidone;long acting injectable risperidone
22 Antipsychotic Effects on Brain Function in Schizophrenia Unknown status NCT01913327 Phase 4 Aripiprazole;Risperidone;Modafinil
23 Donepezil Double Blind Trial for ECT Memory Disfunction Unknown status NCT00465283 Phase 4 Donepezil
24 Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia Unknown status NCT00469664 Phase 4 Guanfacine/Tenex
25 Effect of Slow-release Melatonin (Circadin®) Therapy on Idiopathic RBD: a Pilot Study Unknown status NCT02836743 Phase 4 Circadin;Placebo
26 Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia Unknown status NCT02282085 Phase 4 Aripiprazole Once-Monthly;Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)
27 Electroconvulsive Therapy (ECT) in Patients With Super Refractory Schizophrenia Unknown status NCT02049021 Phase 4
28 Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia Unknown status NCT02040883 Phase 4 Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole;Tandospirone
29 Alleviating the Metabolic Side Effects of Antipsychotic Medications Unknown status NCT01567124 Phase 4 Moxonidine;Placebo;Moxonidine;Placebo
30 Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia Unknown status NCT01300364 Phase 4 Reboxetine;citalopram (SSRI)
31 Reduction of Cardiovascular Risk in Severe Mental Illness Unknown status NCT01182012 Phase 4
32 Minocycline as an Adjunctive Therapy for Schizophrenia: a Randomized Controlled Study Unknown status NCT01133080 Phase 4 Minocycline;placebo
33 Trial for Antidepressant Treatment for Negative Symptom of Schizophrenia With NRG1 Risk Genotype Unknown status NCT01078870 Phase 4 Lexapro;Cymbalta;Placebo
34 Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine Unknown status NCT01047215 Phase 4 Aripiprazole; Quetiapine
35 Contrasting the Brain Effects of Risperidone and Invega With Functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) Scanning Unknown status NCT00937261 Phase 4 Risperidone;Paliperidone
36 Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone Unknown status NCT00480844 Phase 4 Sertindole;Risperidone
37 Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia Unknown status NCT00395915 Phase 4 aripiprazole
38 The New Strategy for Pharmacological Treatment in People With Schizophrenia Unknown status NCT00352339 Phase 4 Rispridoen and Aripiprazole;Risperidne;Abilify
39 Identification and Treatment of the Liability to Develop Schizophrenia Unknown status NCT00305474 Phase 4 Risperidone
40 PREvent First Episode Relapse (PREFER) Unknown status NCT00220714 Phase 4 atypical antipsychotics:oral vs. long-acting route
41 Optimization of Acute Treatment in First Episode Schizophrenia Unknown status NCT00157378 Phase 4 Risperidone, Haloperidol
42 Effect of Music Over the Tolerance to Colonoscopy. Unknown status NCT01285284 Phase 4
43 Testosterone Patch's Effects on the Cardiovascular System and Libido Unknown status NCT01208038 Phase 4 Intrinsa Transdermal testosterone patch
44 Perioperative Pregabalin Use, Rehabilitation, Pain Outcomes and Anxiety Following Hip Surgery Unknown status NCT00762099 Phase 4 Pregabalin;Placebo
45 Sequenced Therapies for Comorbid and Primary Insomnias Unknown status NCT01651442 Phase 4 Zolpidem;Trazodone
46 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
47 Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients Unknown status NCT01399450 Phase 4 paliperidone
48 Hyperventilation Combined With Etomidate or Ketamine Anesthesia in ECT Treatment of Major Depression Unknown status NCT02924090 Phase 4 Etomidate;Ketamine
49 Effect of Zinc Supplementation on Appetite and Growth in Primary Malnourished Children Unknown status NCT03098810 Phase 4 Zinc sulphate
50 The Effect of 21-Days Intranasal Oxytocin on Patients With Post Traumatic Stress Disorder (PTSD) Unknown status NCT02336568 Phase 4 Oxytoine;PLACEBO

Search NIH Clinical Center for Psychotic Disorder

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Psychotic Disorder

Anatomical Context for Psychotic Disorder

MalaCards organs/tissues related to Psychotic Disorder:

42
Brain, Testes, Heart, Eye, Cortex, Prefrontal Cortex, Skin

Publications for Psychotic Disorder

Articles related to Psychotic Disorder:

(show top 50) (show all 491)
# Title Authors Year
1
Accelerated Aging of Functional Brain Networks Supporting Cognitive Function in Psychotic Disorders. ( 30739807 )
2019
2
Prevalence rate of social anxiety disorder in individuals with a psychotic disorder: A systematic review and meta-analysis. ( 30722947 )
2019
3
Group cognitive behavioural therapy for Chinese patients with psychotic disorder: A feasibility controlled study. ( 30639991 )
2019
4
17 D2 Receptor Partial Agonists in Dual Disorders: Use of Aripiprazole in Psychotic Disorder and Comorbid Substance Use Disorder. ( 30859946 )
2019
5
The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. ( 30902669 )
2019
6
Cannabis-related psychotic disorder upon relapse to cannabis use: A case series and possible neurobiological implications. ( 29524790 )
2018
7
Mentalizing impairment as a mediator between reported childhood abuse and outcome in nonaffective psychotic disorder. ( 29145104 )
2018
8
No major influence of regular tobacco smoking on cerebrospinal fluid monoamine metabolite concentrations in patients with psychotic disorder and healthy individuals. ( 29482043 )
2018
9
Auditory steady state response deficits are associated with symptom severity and poor functioning in patients with psychotic disorder. ( 29807805 )
2018
10
Treatment of a Patient with Psychotic Disorder Undergoing Haemodialysis: a Case Report. ( 29864754 )
2018
11
Care Pathways Before First Diagnosis of a Psychotic Disorder in Adolescents and Young Adults. ( 29361848 )
2018
12
Sibling bullying in middle childhood and psychotic disorder at 18 years: a prospective cohort study. ( 29429415 )
2018
13
Mortality Rates After the First Diagnosis of Psychotic Disorder in Adolescents and Young Adults. ( 29387876 )
2018
14
Evidence that reduced gray matter volume in psychotic disorder is associated with exposure to environmental risk factors. ( 29174764 )
2018
15
Electroencephalographic delta/alpha frequency activity differentiates psychotic disorders: a study of schizophrenia, bipolar disorder and methamphetamine-induced psychotic disorder. ( 29643331 )
2018
16
Is BDNF-Val66Met polymorphism associated with psychotic experiences and psychotic disorder outcome? Evidence from a 6 years prospective population-based cohort study. ( 29785763 )
2018
17
Prevalence Rate and Risk Factors of Victimization in Adult Patients With a Psychotic Disorder: A Systematic Review and Meta-analysis. ( 29547958 )
2018
18
Combined NMDA Inhibitor Use in a Patient With Multisubstance-induced Psychotic Disorder. ( 29401155 )
2018
19
The development of an occupational therapy intervention for adults with a diagnosed psychotic disorder following discharge from hospital. ( 29721331 )
2018
20
Telephone-delivered psychosocial interventions targeting key health priorities in adults with a psychotic disorder: systematic review. ( 29798730 )
2018
21
Childhood trauma- and cannabis-associated microstructural white matter changes in patients with psychotic disorder: a longitudinal family-based diffusion imaging study. ( 29807550 )
2018
22
Assessment of Motivations and Willingness to Participate in Research of Outpatients With Anxiety, Mood, and Psychotic Disorders. ( 30047823 )
2018
23
Neuroanatomical deficits shared by youth with autism spectrum disorders and psychotic disorders. ( 30569528 )
2018
24
Risk of non-affective psychotic disorder or bipolar disorder in autism spectrum disorder: a longitudinal register-based study in the Netherlands. ( 30460888 )
2018
25
Use of schizophrenia and bipolar disorder polygenic risk scores to identify psychotic disorders. ( 30113282 )
2018
26
Out-of-pocket health expenditures in patients with bipolar disorder, anxiety, schizophrenia and other psychotic disorders: findings from a study in a psychiatry outpatient clinic in Turkey. ( 29184969 )
2018
27
Impact of synthetic cannabinoid use on hospital stay in patients with bipolar disorder versus schizophrenia, or other psychotic disorders. ( 29329043 )
2018
28
Comorbid Diagnosis of Psychotic Disorders in Borderline Personality Disorder: Prevalence and Influence on Outcome. ( 29593589 )
2018
29
Motor activity patterns in acute schizophrenia and other psychotic disorders can be differentiated from bipolar mania and unipolar depression. ( 30312969 )
2018
30
Psychotic disorder symptom rating scales: Are dichotomous or multi-point scales more clinically useful?-An ICD-11 field study. ( 30017460 )
2018
31
ACUTE SCHIZOPHRENIA-LIKE PSYCHOTIC DISORDER: A CRITICAL APPRAISAL OF ITS DIAGNOSTIC VALIDITY THROUGH A CASE SERIES. ( 30023137 )
2018
32
The prevalence of substance-induced psychotic disorder in methamphetamine misusers: A meta-analysis. ( 30041133 )
2018
33
Cognitive Functioning in Schizophrenia, Methamphetamine-induced Psychotic Disorder, and Healthy People: A Comparative Study. ( 30211136 )
2018
34
Acute Polymorphic Psychotic Disorder: Concepts, Empirical Findings, and Challenges for ICD-11. ( 30256333 )
2018
35
Corrigendum to "Long-term course of negative symptom subdomains and relationship with outcome in patients with a psychotic disorder" [Schizophr. Res. 193 (2018) 173-181]. ( 30314649 )
2018
36
Shared psychotic disorder in children and young people: a systematic review. ( 30328525 )
2018
37
An implicit threat: dolutegravir-induced schizophrenic brief psychotic disorder and persistent cenesthopathy. ( 30407255 )
2018
38
Care of Youth in Their First Emergency Presentation for Psychotic Disorder: A Population-Based Retrospective Cohort Study. ( 30418709 )
2018
39
Characteristics and outcomes of young people with substance induced psychotic disorder. ( 30471979 )
2018
40
Correction: Cognitive Performance and Long-Term Social Functioning in Psychotic Disorder: A Three-Year Follow-Up Study. ( 30475906 )
2018
41
BEATVIC, a body-oriented resilience therapy using kickboxing exercises for people with a psychotic disorder: a feasibility study. ( 30537937 )
2018
42
Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial. ( 30558978 )
2018
43
Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics. ( 30700975 )
2018
44
Delays and barriers to the commencement of clozapine in eligible people with a psychotic disorder: A literature review. ( 29984888 )
2018
45
Electrocortical Responses to Emotional Stimuli in Psychotic Disorders: Comparing Schizophrenia Spectrum Disorders and Affective Psychosis. ( 30505284 )
2018
46
Increased mortality among people with schizophrenia and other non-affective psychotic disorders in the community: A systematic review and meta-analysis. ( 29723811 )
2018
47
The effect of body mass index on glucagon-like peptide receptor gene expression in the post mortem brain from individuals with mood and psychotic disorders. ( 30409537 )
2018
48
Intellectual Disability and Psychotic Disorders in Children: Association With Maternal Severe Mental Illness and Exposure to Obstetric Complications in a Whole-Population Cohort. ( 30278792 )
2018
49
Diagnostic differences in verbal learning strategies and verbal memory in patients with mood disorders and psychotic disorders. ( 30273898 )
2018
50
Association between family history of mental disorders and outcome in psychotic disorders. ( 30384280 )
2018

Variations for Psychotic Disorder

Expression for Psychotic Disorder

Search GEO for disease gene expression data for Psychotic Disorder.

Pathways for Psychotic Disorder

Pathways related to Psychotic Disorder according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.67 COMT DRD1 DRD2 DRD3 DRD4 MAOB
2
Show member pathways
12.57 BDNF DRD1 DRD2 DRD3 DRD4
3 12.3 COMT DTNBP1 RGS4 SLC1A1 SYN2
4 12.11 DRD1 DRD2 DRD3 DRD4
5 11.78 HTR2A MAOB SLC6A4
6 11.72 DRD3 DRD4 HTR2A
7
Show member pathways
11.71 DRD2 DRD3 DRD4
8
Show member pathways
11.69 BDNF DRD1 DRD2 MAOB
10
Show member pathways
11.36 DAO MAOB PRODH
11 11.23 BDNF DRD1 DRD2
12
Show member pathways
11.06 DRD1 DRD2 DRD3 DRD4 HTR2A
13
Show member pathways
10.69 COMT MAOB
14 10.67 DRD1 DRD2 DRD3
15 10.64 COMT MAOB

GO Terms for Psychotic Disorder

Cellular components related to Psychotic Disorder according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.93 DISC1 DTNBP1 NRG1 NRXN1 SYN2
2 dendrite GO:0030425 9.85 BDNF COMT DRD2 DRD4 HTR2A
3 postsynaptic density GO:0014069 9.83 DISC1 DRD2 DTNBP1 SYN2
4 axon GO:0030424 9.8 BDNF COMT DRD2 DTNBP1 HTR2A NRG1
5 Schaffer collateral - CA1 synapse GO:0098685 9.67 DTNBP1 NRXN1 SYN2
6 synaptic vesicle membrane GO:0030672 9.65 DRD2 DTNBP1 SYN2
7 endocytic vesicle GO:0030139 9.61 DRD2 DRD3 NRXN1
8 integral component of postsynaptic membrane GO:0099055 9.56 DRD1 DRD2 HTR2A SLC6A4
9 GABA-ergic synapse GO:0098982 9.55 DRD1 DRD2 DRD3 NRG1 NRXN1
10 dopaminergic synapse GO:0098691 9.51 DRD2 DRD3
11 integral component of presynaptic membrane GO:0099056 9.35 DRD1 DRD2 HTR2A NRXN1 SLC6A4
12 glutamatergic synapse GO:0098978 9.28 DRD1 DRD2 DRD3 DRD4 DTNBP1 HTR2A
13 plasma membrane GO:0005886 10.25 COMT DISC1 DRD1 DRD2 DRD3 DRD4
14 integral component of plasma membrane GO:0005887 10.02 DRD1 DRD2 DRD3 DRD4 HTR2A NRG1

Biological processes related to Psychotic Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Name GO ID Score Top Affiliating Genes
1 locomotory behavior GO:0007626 9.9 DRD1 DRD2 DRD3 NRG1
2 cellular calcium ion homeostasis GO:0006874 9.88 DRD3 DRD4 HTR2A
3 response to toxic substance GO:0009636 9.88 DRD2 MAOB SLC6A4
4 memory GO:0007613 9.88 BDNF DRD1 HTR2A SLC6A4
5 learning GO:0007612 9.86 COMT DRD1 DRD3 NRXN1
6 social behavior GO:0035176 9.85 DRD3 DRD4 NRXN1 SLC6A4
7 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.84 DRD1 DRD4 HTR2A
8 regulation of synaptic vesicle exocytosis GO:2000300 9.84 DRD1 DRD2 DTNBP1 HTR2A
9 visual learning GO:0008542 9.82 DRD1 DRD2 DRD3
10 response to cocaine GO:0042220 9.81 DRD1 DRD2 DRD3 RGS4
11 regulation of dopamine secretion GO:0014059 9.8 DRD3 DTNBP1 HTR2A
12 response to ethanol GO:0045471 9.8 DRD2 DRD3 MAOB RGS4
13 synapse assembly GO:0007416 9.8 BDNF DRD1 DRD2 NRG1 NRXN1
14 response to morphine GO:0043278 9.79 DRD2 DRD3 RGS4
15 arachidonic acid secretion GO:0050482 9.78 DRD2 DRD3 DRD4
16 temperature homeostasis GO:0001659 9.77 DRD1 DRD2 HTR2A
17 negative regulation of protein secretion GO:0050709 9.75 DRD2 DRD3 DRD4
18 synaptic transmission, dopaminergic GO:0001963 9.74 DRD1 DRD2 DRD3
19 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.71 DRD2 DRD3
20 positive regulation of kinase activity GO:0033674 9.71 DRD4 HTR2A
21 striatum development GO:0021756 9.71 DRD1 DRD2
22 grooming behavior GO:0007625 9.7 DRD1 DRD2
23 positive regulation of renal sodium excretion GO:0035815 9.7 DRD2 DRD3
24 G protein-coupled receptor internalization GO:0002031 9.7 DRD2 DRD3
25 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.7 DRD2 DRD3 DRD4
26 response to drug GO:0042493 9.7 COMT DRD1 DRD2 DRD3 HTR2A MAOB
27 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.69 DRD3 DRD4
28 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.69 DRD1 DRD3
29 neurotransmitter catabolic process GO:0042135 9.69 COMT MAOB
30 peristalsis GO:0030432 9.68 DRD1 DRD2
31 regulation of dopamine metabolic process GO:0042053 9.68 DRD1 DRD4
32 behavioral response to ethanol GO:0048149 9.68 DRD2 DRD4
33 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.68 DRD2 HTR2A
34 negative regulation of voltage-gated calcium channel activity GO:1901386 9.67 DRD2 DRD4
35 dopamine catabolic process GO:0042420 9.67 COMT MAOB
36 synaptic vesicle clustering GO:0097091 9.67 NRXN1 SYN2
37 dopamine receptor signaling pathway GO:0007212 9.67 DRD1 DRD2 DRD3 DRD4
38 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.65 DRD1 DRD2
39 cerebral cortex GABAergic interneuron migration GO:0021853 9.65 DRD1 DRD2
40 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.65 DRD1 DRD2 DRD3
41 response to amphetamine GO:0001975 9.65 DRD1 DRD2 DRD3 DRD4 RGS4
42 proline catabolic process GO:0006562 9.64 DAO PRODH
43 acid secretion GO:0046717 9.64 DRD2 DRD3
44 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.63 DRD2 DRD4
45 regulation of locomotion involved in locomotory behavior GO:0090325 9.63 DRD2 DRD3
46 negative regulation of dopamine receptor signaling pathway GO:0060160 9.63 DRD2 DRD3 RGS4
47 prepulse inhibition GO:0060134 9.62 DRD1 DRD2 DRD3 NRXN1
48 response to histamine GO:0034776 9.61 DRD2 DRD3 DRD4
49 behavioral response to cocaine GO:0048148 9.35 DRD1 DRD2 DRD3 DRD4 HTR2A
50 dopamine metabolic process GO:0042417 9.02 COMT DRD1 DRD2 DRD3 DRD4

Molecular functions related to Psychotic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.56 DRD2 DRD3 DRD4 HTR2A
2 G-protein alpha-subunit binding GO:0001965 9.5 DRD1 HTR2A RGS4
3 adrenergic receptor activity GO:0004935 9.4 DRD2 DRD3
4 serotonin binding GO:0051378 9.37 HTR2A SLC6A4
5 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.33 DRD2 DRD3 DRD4
6 dopamine binding GO:0035240 9.26 DRD1 DRD2 DRD3 DRD4
7 dopamine neurotransmitter receptor activity GO:0004952 8.92 DRD1 DRD2 DRD3 DRD4

Sources for Psychotic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
77